Sam Brusco, Associate Editor05.21.24
Glooko has announced the appointments of Dr. David Pass and Adam Hameed as the newly-created roles of presidents of Life Sciences and Connected Care, respectively.
Dr. Pass has extensive experience in pharmaceuticals, medical devices , and healthcare technology. He was previously chief operating officer and chief commercial officer at Gelesis and VP of marketing at Boehringer Ingelheim (BI) for diabetes. At BI he built a multi-billion-dollar alliance with Eli Lilly & Company.
Hameed previously served as chief growth officer of Andros, as well as chief development officer of Cricket Health (now part of Interwell Health). Before that, he had leadership positions at Optum, leading payer sales and account management for OptumHealth and several go-to-market teams at OptumInsight.
Glooko said by creating these new positions it poises itself for further growth and innovation in chronic condition management. The new roles, the Palo Alto, Calif.-based company said, emphasize its commitment to digital companions/therapeutics, clinical research, real-world data, and device integrations.
"We are thrilled to welcome David and Adam as Presidents of Life Sciences and Connected Care," said Russ Johannesson, CEO of Glooko. "With David and Adam leading our market facing strategies for these differentiated business units, we are confident that their unique experience and close collaboration will help Glooko drive significant new value for our customers, users and partners globally."
Using Glooko, data can be synced from a meter, insulin pump or pen, continuous glucose monitor (CGM), food app, activity tracker, and blood pressure device to view all data in one location. Meals and activity can be logged, and the company’s food database contains more than 500,000 items.
Glooko is globally deployed in over 30 countries and 8,000+ clinical locations, the company says. It began partnerships with digital therapeutics company Hedia and multinational healthcare and pharmaceutical company Sanofi last year.
Dr. Pass has extensive experience in pharmaceuticals, medical devices , and healthcare technology. He was previously chief operating officer and chief commercial officer at Gelesis and VP of marketing at Boehringer Ingelheim (BI) for diabetes. At BI he built a multi-billion-dollar alliance with Eli Lilly & Company.
Hameed previously served as chief growth officer of Andros, as well as chief development officer of Cricket Health (now part of Interwell Health). Before that, he had leadership positions at Optum, leading payer sales and account management for OptumHealth and several go-to-market teams at OptumInsight.
Glooko said by creating these new positions it poises itself for further growth and innovation in chronic condition management. The new roles, the Palo Alto, Calif.-based company said, emphasize its commitment to digital companions/therapeutics, clinical research, real-world data, and device integrations.
"We are thrilled to welcome David and Adam as Presidents of Life Sciences and Connected Care," said Russ Johannesson, CEO of Glooko. "With David and Adam leading our market facing strategies for these differentiated business units, we are confident that their unique experience and close collaboration will help Glooko drive significant new value for our customers, users and partners globally."
About Glooko
The company’s personalized, intelligent, connected care platform aims to improve health outcomes of people suffering from chronic conditions. Its technologies seek to drive patient engagement and adherence with digital therapeutics and accelerating the speed of clinical trials.Using Glooko, data can be synced from a meter, insulin pump or pen, continuous glucose monitor (CGM), food app, activity tracker, and blood pressure device to view all data in one location. Meals and activity can be logged, and the company’s food database contains more than 500,000 items.
Glooko is globally deployed in over 30 countries and 8,000+ clinical locations, the company says. It began partnerships with digital therapeutics company Hedia and multinational healthcare and pharmaceutical company Sanofi last year.